Switch theme
Sign up to access all valuation multiples
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
2020
155
LTM Revenue $38.5M
LTM EBITDA n/a
-$76.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tango Therapeutics has a last 12-month revenue of $38.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Tango Therapeutics achieved revenue of $42.1M and an EBITDA of -$143M.
Tango Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tango Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $36.5M | $42.1M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$112M | -$143M | XXX | XXX | XXX |
| EBITDA Margin | -306% | -340% | XXX | XXX | XXX |
| Net Profit | -$108M | -$102M | XXX | XXX | XXX |
| Net Margin | -296% | -242% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Tango Therapeutics's stock price is $1.
Tango Therapeutics has current market cap of $145M, and EV of -$76.6M.
See Tango Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$76.6M | $145M | XXX | XXX | XXX | XXX | $-1.25 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Tango Therapeutics has market cap of $145M and EV of -$76.6M.
Tango Therapeutics's trades at -2.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Tango Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Tango Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$76.6M | XXX | XXX | XXX |
| EV/Revenue | -1.8x | XXX | XXX | XXX |
| EV/EBITDA | 0.5x | XXX | XXX | XXX |
| P/E | -1.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTango Therapeutics's NTM/LTM revenue growth is -23%
Tango Therapeutics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Tango Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Tango Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Tango Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -340% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -363% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 104% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 342% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 446% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tango Therapeutics acquired XXX companies to date.
Last acquisition by Tango Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Tango Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Tango Therapeutics founded? | Tango Therapeutics was founded in 2020. |
| Where is Tango Therapeutics headquartered? | Tango Therapeutics is headquartered in United States of America. |
| How many employees does Tango Therapeutics have? | As of today, Tango Therapeutics has 155 employees. |
| Who is the CEO of Tango Therapeutics? | Tango Therapeutics's CEO is Dr. Barbara L. Weber, M.D.. |
| Is Tango Therapeutics publicy listed? | Yes, Tango Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Tango Therapeutics? | Tango Therapeutics trades under TNGX ticker. |
| When did Tango Therapeutics go public? | Tango Therapeutics went public in 2021. |
| Who are competitors of Tango Therapeutics? | Similar companies to Tango Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Tango Therapeutics? | Tango Therapeutics's current market cap is $145M |
| What is the current revenue of Tango Therapeutics? | Tango Therapeutics's last 12-month revenue is $38.5M. |
| What is the current EV/Revenue multiple of Tango Therapeutics? | Current revenue multiple of Tango Therapeutics is -2.0x. |
| What is the current revenue growth of Tango Therapeutics? | Tango Therapeutics revenue growth between 2023 and 2024 was 15%. |
| Is Tango Therapeutics profitable? | Yes, Tango Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
